

Table 4. Reactivity of Commercial Type-Specific Adenovirus Antibodies to Immobilized Peptides

Vendor	Ab Specificity	Sample I.D.	Biosensor results in Response units (RU)						
			Peptide:						
			HVR1	HVR2	HVR3	HVR4	HVR5	HVR6	HVR7
Biogenesis	Goat anti-Ad2 hexon	post	25	3	17	3	5	15	15
Accurate	Murine anti-Ad penton (65 KD)	post	0	0	0	0	0	0	0
Biodesign	Goat anti-Ad2 hexon	post	30	10	ND	8	13	ND	ND
Biospecific	anti-Ad6	post	ND	ND	16	ND	ND	10	13
Biospecific	anti-Ad3	post	ND	ND	0	ND	ND	0	0
Lee Biol.	Rabbit anti-Ad5	pre post	0 255	0 0	0 6	0 0	0 0	0 8	0 10

pre = pre-dosed sample
post = post-dosed sample
ND = Not Determined

Positive results are indicated in **Bold** based on the following criteria:

- 1) Ratio of RU of post sample / RU of pre sample ≥ 2.0 OR
- 2) Post sample (without pre) with a binding greater than 50 RU

REF ID: A11111

Table 5. Reactivity of Pre-Clinical Serum Samples to Immobilized Peptides from Pigs that Received rAd5

Sample I.D.	Timepoint	Peptide:	Biosensor results in Response units (RU)						
			HVR1	HVR2	HVR3	HVR4	HVR5	HVR6	HVR7
377	pre		66	46	101	39	41	87	139
5	D15	1085 ✓	58	58	112	79	58	108	151
384	pre	73	71	99	87	52	57	98	129
8	D15	795 ✓	57	87	81	131 ✓	51	70	102
8	D29	1620 ✓	65	81	83	111 ✓	62	71	101
393	pre	96	199	83	83	83	100	65	80
12	D15	483	127	71	92	140	57	95	72
12	D29	1490 ✓	107	92	201 ✓	201 ✓	63	104	99
12	D48	665 ✓	113	107	177 ✓	177 ✓	94	86	91
389	pre	48	45	73	34	34	48	69	87
11	D15	729 ✓	39	52	32	32	50	53	64
11	D29	1494 ✓	61	62	125 ✓	125 ✓	68	58	80
11	D48	1024 ✓	66	61	136 ✓	136 ✓	65	54	84
390	pre	72	80	74	77	77	73	60	94
7	D15	936 ✓	64	70	62	62	56	60	81
7	D29	1200 ✓	66	69	75	75	60	58	76
385	pre	107	80	65	62	62	72	59	81
3	D15	567 ✓	49	41	41	41	42	40	55

pre = pre-dose sample
D = Day after dosing
Positive results are indicated in **Bold** based on the following ratio:
RU of post sample / RU of pre sample \geq 2.0

Table 6. Reactivity of Serum Samples to Immobilized Peptides from Patients with Non-Small Cell Lung Cancer Administered rAd5

Patient Initials	Timepoint	Peptide:	Biosensor results in Response units (RU)						
			HVR1	HVR2	HVR3	HVR4	HVR5	HVR6	HVR7
ER	PRE		19	19	38	14	22	22	28
	D7		ND	ND	ND	ND	ND	ND	ND
	D14		26	27	41	21	29	24	31
	D21		21	22	37	17	18	21	27
FH	PRE		24	27	50	25	26	73	30
	D3		21	21	ND	27	23	ND	ND
	D7		386 ✓	17	ND	20	16	ND	ND
	D14		1161 ✓	34	55	34	37	83	32
IK	D21		845 ✓	33	48	29	34	68	25
	PRE		24	20	37	12	28	17	21
	D7		2045 ✓	14	ND	42 ✓	15	ND	ND
	D14		8266 ✓	25	37	101 ✓	25	17	21
HH	D21		7549 ✓	13	ND	61 ✓	9	ND	ND
	D28		8385 ✓	29	39	87 ✓	37	18	23
	2MO.		2796 ✓	10	ND	18	9	ND	ND
	PRE		33	20	61	19	22	38	51
MK	D3		30	13	ND	13	5	ND	ND
	D7		60	22	ND	22	18	ND	ND
	D14		660 ✓	23	45	17	16	28	43
	D21		699 ✓	22	ND	15	9	ND	ND
SM	D28		433 ✓	25	41	18	20	27	38
	2MO.		170 ✓	15	ND	9	5	ND	ND
	PRE		11	14	29	13	11	15	13
	D3		ND	ND	ND	ND	ND	ND	14
SM	D7		14	18	29	16	16	16	1230
	PRE		23	23	37	16	32	16	1026
	D6		108 ✓	20	40	14	27	20	523
	D27		173 ✓	12	29	9	21	19	ND
ER	D48		151 ✓	7	ND	4	11	ND	ND

D = Day after dosing
 ND = Not Determined
 pre = pre-dose
 MO. = Month's after dosing
 Positive results are indicated in Bold based on the following ratio:
 RU of post sample / RU of pre sample \geq 2.0

07:11:34.50 "00:00:00"

A. Patients with Recurrent & Malignant Head and Neck Cancer

Patient	Timepoint	Peptide:
---------	-----------	----------

B. Patient with Recurrent Melanoma & Breast Cancer

Patient	Timepoint	Per
---------	-----------	-----

C. Patient with Peritoneal Carcinomatosis

Patient Initials	Timepoint
------------------	-----------

Patient Initials	Timepoint	Peptide:	HVR1	HVR3	HVR4	HVR7
VKA	PRE		7	35	16	12
	D2		10	33	17	16
	D3		8	30	13	17
	D7		14	49	26	17
	D14		41	36	16	29 ✓
	D21		45 ✓	44	25	26 ✓
	D28		38 ✓	31	16	25 ✓

D. Patients with Hepatocellular Carcinoma

Patient Initials	Timepoint	Peptide:	HVR1	HVR3	HVR4	HVR7
JT	PRE		50	206	40	132
	D2		10	33	17	16
	D3		25	136	18	85
	D7		1629 ✓	109	27	73
	D14		7538 ✓	171	108 ✓	111
	D21		5208 ✓	187	102 ✓	116
	D28		3837 ✓	174	83 ✓	108
WMF	PRE		17	24	20	16
	D3		17	23	20	18
	D7		68 ✓	18	17	15
	D14		163 ✓	27	22	21
	D28		106 ✓	19	18	19
DFB	PRE		12	21	13	14
	D3		14	20	14	18
	D7		49 ✓	15	12	16
	D14		1226 ✓	26	14	19
	D21		606 ✓	22	10	14
RK	D28		414 ✓	32	19	23
	PRE		21	21	14	19
	D3		19	18	12	19
	D7		40	25	20	25
	D14		113 ✓	21	15	18
	D21		75 ✓	19	13	19
	D28		88 ✓	32	22	32

PRE = pre-dose

D = Day after dosing

Positive results are indicated in Bold based on the following ratio:

RU of post sample / RU of pre sample ≥ 2.0

03200203121940

Table 9.
C95-177-01- RECURRENT OR METASTATIC HEAD & NECK CANCER

INITIALS	SAMPLE	HVR1	HVR3	HVR4	HVR7
TGL	PRE	11.3	31.5	16.6	15.2
	D3	8.7	23.6	12.1	12.4
	D8	9.5	28.9	14	13.4
	D15	9.2	27	13.6	13.3
	D22	11	30.7	16.3	15.5
	D28	10.9	29.3	15.6	16.6
RWT	PRE	52.5	59	26.6	31.8
	D3	46.8	49.8	23	28.3
	D10	58	52.3	27.9	36.3
	D14	41.5	35	17.4	22.9

195-082-04 - RECURRENT MELANOMA OR BREAST CANCER

INITIALS	SAMPLE	HVR1	HVR3	HVR4	HVR7
ES	PRE	27	27.4	23.5	19.8
	D3	22.8	25.8	20.3	17.8
	D7	53.7	27.4	23.2	19.4
	D14	252	28.2	21.7	18.6
	D21	185	27.6	20.8	17.7
	D28	78.6	14.6	10	8.2

C95-084-01 - PERITONEAL CARCINOMATOSIS

INITIALS	SAMPLE	HVR1	HVR3	HVR4	HVR7
VKA	PRE	7.4	35	16.2	12
	D2	10.1	33	16.9	15.6
	D3	7.7	29.7	13.1	16.5
	D7	14	48.6	26	17.4
	D14	41	36	16	28.9
	D21	44.5	43.8	25.4	26.1
	D28	38.1	30.6	16.3	24.7

C95-063-01 – HEPATOCELLULAR CARCINOMA

INITIALS	SAMPLE	HVR1	HVR3	HVR4	HVR7
CLL	PRE	8.3	15.9	12.6	11.7
	D3	6.8	17.8	11.8	10.4
JT	PRE	50.3	205.8	39.7	131.7
	D2	10.1	33	16.9	15.6
	D3	24.6	135.6	18	85.1
	D7	1629	108.5	26.6	72.6
	D14	7538	170.6	108	110.6
	D21	5208	186.5	102	116.1
EL	D28	3837	173.8	82.5	107.8
	PRE	23.4	26.6	21.4	22.4
JK	PRE2	21.7	33.7	20.6	33.8
	PRE1	17	28.8	15.9	26.5
WMF	PRE	16.7	23.5	19.5	15.8
	D3	17.3	22.5	19.5	17.5
	D7	87.7	18.3	17	15.3
	D14	163	26.8	22.3	21.4
	D28	106	19.2	17.7	18.9
DFB	PRE	12.3	21	12.6	14
	D3	13.7	20.3	13.9	18.1
	D7	48.7	15.3	11.5	15.6
	D14	1228	26.3	14.3	18.6
	D21	606	22.3	10.4	14.2
RK	D28	414	32.3	19.1	22.6
	PRE	20.7	20.5	14.2	19.2
	D3	18.5	17.5	12.4	19.4
	D7	39.5	24.6	19.5	24.6
	D14	113	21.2	14.9	18
	D21	75.3	19	13.1	19.3
	D28	87.6	31.9	21.9	31.8